AIDSPub Date : 2026-12-01Epub Date: 2026-10-29DOI: 10.1097/QAD.0000000000004611
Diana L T Mukuku, Justen Manasa, Vinie Kouamou
{"title":"HIV cure research cannot ignore nonsubtype B: defective proviruses and immune activation in Africa.","authors":"Diana L T Mukuku, Justen Manasa, Vinie Kouamou","doi":"10.1097/QAD.0000000000004611","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004611","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 12","pages":"1905-1906"},"PeriodicalIF":2.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2026-12-01Epub Date: 2026-07-22DOI: 10.1097/QAD.0000000000004583
Tom Sumner, Rebecca A Clark, Tomos O Prys-Jones, Roel Bakker, Gavin Churchyard, Richard G White
{"title":"New tuberculosis vaccines for people with HIV.","authors":"Tom Sumner, Rebecca A Clark, Tomos O Prys-Jones, Roel Bakker, Gavin Churchyard, Richard G White","doi":"10.1097/QAD.0000000000004583","DOIUrl":"10.1097/QAD.0000000000004583","url":null,"abstract":"<p><strong>Background: </strong>In 2024, tuberculosis (TB) caused 160 000 deaths in people with HIV (PWH). Several new TB vaccines are in development. The best way to use new vaccines to reduce the TB burden in PWH, and how this may vary by setting, is unknown.</p><p><strong>Methods: </strong>We used a mathematical model to simulate TB vaccination in 15 high HIV/TB burden countries with varying HIV prevalence and ART coverage. We estimated the impact of vaccination with 50% efficacy against TB disease targeted by HIV status and explored how the impact depends on assumptions about vaccine efficacy by HIV and ART status.</p><p><strong>Results: </strong>Vaccines that do not work or are contraindicated in PWH could avert 5-13% of cases in PWH between 2030 and 2050 through the indirect effect of vaccinating people without HIV. Vaccines that were equally effective in PWH and people without HIV could avert 19-25% of cases in PWH. The impact of strategies targeted by HIV status depended on country-specific factors. In countries with high ART coverage, vaccination of PWH may be more effective at averting cases in PWH than vaccination of HIV-uninfected individuals. Strategies targeting PWH are likely to be more efficient than those targeting HIV-uninfected individuals.</p><p><strong>Conclusion: </strong>The most impactful way to use new TB vaccines to reduce the burden of TB in PWH will depend on setting-specific factors, including ART coverage and the efficacy of the vaccine in PWH. Vaccinating PWH is likely to be an efficient use of resources to reduce TB burden in PWH.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1842-1852"},"PeriodicalIF":2.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2026-12-01Epub Date: 2026-07-06DOI: 10.1097/QAD.0000000000004580
Renato Bobadilla, Tara L Tenenbaum, Christophe Vanpouille, Alan Wells, Antoine Chaillon, Joseph Lonergan, Leticia Muttera, Liliana Harkness, Susan J Little, Davey Smith, Sara Gianella
{"title":"Impact of influenza and pneumococcal vaccines on inflammatory response during suppressive antiretroviral therapy.","authors":"Renato Bobadilla, Tara L Tenenbaum, Christophe Vanpouille, Alan Wells, Antoine Chaillon, Joseph Lonergan, Leticia Muttera, Liliana Harkness, Susan J Little, Davey Smith, Sara Gianella","doi":"10.1097/QAD.0000000000004580","DOIUrl":"10.1097/QAD.0000000000004580","url":null,"abstract":"<p><strong>Objective: </strong>We performed a secondary analysis of a randomized clinical trial that evaluated stimulation of HIV reservoir through routine vaccines (NCT02707692) to characterize vaccine-induced inflammatory responses and their association with HIV virologic measures following influenza and pneumococcal vaccination in people with HIV (PWH) on suppressive antiretroviral therapy (ART).</p><p><strong>Design: </strong>Prospective, randomized, double-blinded, placebo-controlled, crossover trial evaluating influenza and pneumococcal vaccines.</p><p><strong>Methods: </strong>Fifty-four PWH on ART were enrolled. Blood was collected at baseline and days 2, 4, 7, 14, and 30 postvaccination. Of 41 cytokines quantified by Luminex, 19 with >30% detectable values postbaseline were analyzed. Cellular HIV RNA and DNA were measured by ddPCR. Analyses included partial least squares discriminant analysis (PLSDA) and linear mixed-effects models.</p><p><strong>Results: </strong>Fifty-three participants contributed ≥1 postvaccination visit. We observed no distinct cytokine profile by vaccine type or placebo. Pneumococcal vaccination induced transient increases in LBP [0.231; 95% confidence interval (CI): [0.126, 0.336]; P = 0.0003) and C-reactive protein (0.643; 95% CI: [0.482, 0.804]; P < 0.0001), while influenza vaccination was associated with a modest decrease in RANTES (-0.116; 95% CI: [-0.188, -0.043]; P = 0.0218) compared with placebo. Independent of vaccine type, HIV DNA Gag levels were inversely associated with interleukin (IL)-16 and RANTES.</p><p><strong>Conclusions: </strong>In PWH on suppressive ART, influenza and pneumococcal vaccination elicited mild and transient changes in individual cytokines, though distinct global cytokine signatures were not observed. This finding supports vaccine safety in PWH, showing no broad inflammatory perturbations. Independent of vaccine type, specific cytokines (IL-16 and RANTES) were associated with HIV reservoir measures, suggesting potential roles in reservoir dynamics and immune activation.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1826-1831"},"PeriodicalIF":2.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2026-12-01Epub Date: 2026-07-27DOI: 10.1097/QAD.0000000000004588
Benjamin H Chi, Deborah Kacanek, Emily Brown, K Rivet Amico, Sharon Huang, Teacler Nematadzira, Elizea Horne, Clemensia Nakabiito, Sharon K Mambiya, Violet Korutaro, Tichaona Vhembo, Michael Whitton, Benjamin Johnston, Olga Varechtchouk, Hans Spiegel, Peter L Anderson, Lynda Stranix-Chibanda
{"title":"Maternal and pregnancy outcomes in women offered daily oral preexposure prophylaxis during pregnancy and postpartum.","authors":"Benjamin H Chi, Deborah Kacanek, Emily Brown, K Rivet Amico, Sharon Huang, Teacler Nematadzira, Elizea Horne, Clemensia Nakabiito, Sharon K Mambiya, Violet Korutaro, Tichaona Vhembo, Michael Whitton, Benjamin Johnston, Olga Varechtchouk, Hans Spiegel, Peter L Anderson, Lynda Stranix-Chibanda","doi":"10.1097/QAD.0000000000004588","DOIUrl":"10.1097/QAD.0000000000004588","url":null,"abstract":"<p><strong>Objective: </strong>To compare maternal safety and pregnancy outcomes among women who did and did not use daily oral emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) for preexposure prophylaxis (PrEP) during pregnancy and postpartum.</p><p><strong>Design: </strong>Parallel cohort design, with follow-up from pregnancy to 6 months postpartum.</p><p><strong>Setting: </strong>Seven research clinics in Malawi, South Africa, Uganda, and Zimbabwe.</p><p><strong>Participants: </strong>Three hundred fifty pregnant women aged 16-24 years at 32 weeks or less gestation, meeting local criteria for PrEP. At entry, PrEP initiators and decliners were enrolled 2 : 1. Participants could start or stop PrEP at any time.</p><p><strong>Main outcome measures: </strong>Maternal adverse events were defined as grade ≥3 signs, symptoms, and diagnoses, and grade ≥2 chemistry abnormalities according to Division of AIDS toxicity tables. Adverse pregnancy outcomes included fetal loss, preterm birth, and small-for-gestational-age.</p><p><strong>Results: </strong>From March to December 2022, 350 eligible participants enrolled: 229 initiating and 121 declining PrEP at entry. Median duration of PrEP use was 34 weeks (interquartile range [IQR]: 16-40). Sixty maternal adverse events were reported over 230.3 person-years (incidence rate: 25.6, 95% confidence interval [95% CI]: 20.0-32.8). Although those on PrEP had higher rates of adverse events, this was not statistically significant (adjusted incidence rate ratio: 1.84, 95% CI: 0.53-6.30). Most frequent grade ≥3 adverse events were complications of pregnancy or delivery. Five (8%) were considered related to PrEP use. Among those with delivery information, 79 (24%) participants reported adverse pregnancy outcomes, with no differences between PrEP groups. No participants acquired HIV infections during follow-up.</p><p><strong>Conclusion: </strong>Daily oral FTC-TDF remains a well tolerated and essential component of HIV prevention in pregnancy.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1864-1873"},"PeriodicalIF":2.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13431001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148597704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2026-12-01Epub Date: 2026-08-13DOI: 10.1097/QAD.0000000000004606
Lauren O'Connor, Anne Monroe, Yun Ji, Anuja Baskaran, Amanda D Castel, Angelo Elmi
{"title":"Longitudinal trends in copy-years viremia associated with mpox acquisition but not mpox severity in people with HIV.","authors":"Lauren O'Connor, Anne Monroe, Yun Ji, Anuja Baskaran, Amanda D Castel, Angelo Elmi","doi":"10.1097/QAD.0000000000004606","DOIUrl":"10.1097/QAD.0000000000004606","url":null,"abstract":"<p><strong>Objectives: </strong>High viral load and low CD4 + cell count may be associated with increased risk of mpox acquisition. However, prior studies have not evaluated whether longitudinal trends in HIV lab measures, measured as the slope over time, are associated with mpox acquisition or severe mpox. Therefore, we evaluated whether longitudinal trends in CD4 + cell count (cells/μl), viral load (copies/ml), and copy-years viremia (CYV) (copies × years/ml) were associated with increased risk of mpox acquisition.</p><p><strong>Design: </strong>We conducted a nested case-control study among participants in the DC Cohort, a longitudinal study on people with HIV (PWH) in Washington, DC.</p><p><strong>Methods: </strong>Cases were defined as participants with mpox and were matched to five controls using risk set-sampling. Both two-stage modeling and joint modeling approaches were used to evaluate whether longitudinal trends in CD4 + cell count, viral load, and CYV were associated with mpox acquisition.</p><p><strong>Results: </strong>We evaluated 53 cases of mpox and 248 matched controls, with 13.7% of cases having severe mpox. An increased slope of CYV was associated with an increased risk of mpox acquisition based on the joint modeling approach, after adjusting for AIDS and known antiretroviral regimen [hazard ratio (95% CI): 1.11 (1.04-1.18)].</p><p><strong>Conclusion: </strong>Clinicians should consider a patient's entire history of viral load, not just viral load measured at one point in time, when evaluating risk of mpox.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1895-1900"},"PeriodicalIF":2.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2026-12-01Epub Date: 2026-09-01DOI: 10.1097/QAD.0000000000004614
Juan Berenguer, Pablo Ryan, Luis Ramos-Ruperto, Luz Martín-Carbonero, Leire Pérez-Latorre, Ignacio De Los Santos, Adriana Pinto, María J Vivancos, Eva Orviz, Beatriz Álvarez, José Sanz, Pilar Ruiz-Seco, Rafael Torres, Marta De Miguel, Herminia Esteban, Inmaculada Jarrín, Salvador Resino, José M Bellón, Juan González-García
{"title":"Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV.","authors":"Juan Berenguer, Pablo Ryan, Luis Ramos-Ruperto, Luz Martín-Carbonero, Leire Pérez-Latorre, Ignacio De Los Santos, Adriana Pinto, María J Vivancos, Eva Orviz, Beatriz Álvarez, José Sanz, Pilar Ruiz-Seco, Rafael Torres, Marta De Miguel, Herminia Esteban, Inmaculada Jarrín, Salvador Resino, José M Bellón, Juan González-García","doi":"10.1097/QAD.0000000000004614","DOIUrl":"10.1097/QAD.0000000000004614","url":null,"abstract":"<p><strong>Objective: </strong>Risk of acute/recent hepatitis C virus infection (ARHCV) and bacterial sexually transmitted infections (STIs) among MSM (MSM-HIV) is heterogeneous. We aimed to identify clinical phenotypes and assess their association with incident ARHCV and bacterial STIs.</p><p><strong>Design: </strong>A prospective multicenter cohort study.</p><p><strong>Methods: </strong>Between 2022 and 2024, MSM-HIV were recruited from 10 centers in Madrid and followed for 12 months with HCV and bacterial STI screening. App-based questionnaires captured behavioral and mental health data. Thirty-eight variables were analyzed using principal component analysis and hierarchical clustering to derive clinical phenotypes.</p><p><strong>Results: </strong>A total of 529 participants were included (median age 41 years). Three phenotypes were identified: CP1 ( n = 328, 62.0%), CP2 ( n = 133, 25.1%), and CP3 ( n = 68, 12.9%), representing different levels of sexual risk, substance use, and prior STI/HCV history. ARHCV incidence was 0.94, 0.72, and 11.76 per 100 person-years in CP1, CP2, and CP3, respectively, and was higher in CP3 than in CP1 (incidence rate ratio [IRR] 12.49, 95% confidence interval [CI] 3.00-73.08) and CP2 (16.25, 2.18-720.93). Bacterial STI incidence was 33.29, 60.83, and 61.76 per 100 person-years, respectively, and was higher in CP2 (IRR 1.83, 95% CI 1.36-2.46) and CP3 (IRR 1.86, 95% CI 1.27-2.68) than in CP1.</p><p><strong>Conclusion: </strong>Clinical phenotypes stratified ARHCV and bacterial STI incidence among MSM-HIV. ARHCV was concentrated in a small high-exposure subgroup, whereas bacterial STIs were more frequent in intermediate and high-exposure phenotypes. Phenotype-based approaches may help guide risk stratification and prevention in HIV care.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1807-1816"},"PeriodicalIF":2.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2026-12-01Epub Date: 2026-07-27DOI: 10.1097/QAD.0000000000004587
Michaeline McGuinty, Pierre Giguère, Jonathan B Angel
{"title":"Cabotegravir/rilpivirine in pregnancy: early insights from clinical practice.","authors":"Michaeline McGuinty, Pierre Giguère, Jonathan B Angel","doi":"10.1097/QAD.0000000000004587","DOIUrl":"10.1097/QAD.0000000000004587","url":null,"abstract":"<p><strong>Objective: </strong>To describe early experience with the use of cabotegravir/rilpivirine (CAB/RPV) in pregnancy and make recommendations based on these observations.</p><p><strong>Design: </strong>This is a case series.</p><p><strong>Setting: </strong>This took place at a multidisciplinary HIV clinic based at an academic centre in Ottawa, Canada.</p><p><strong>Participants: </strong>Women who received CAB/RPV during pregnancy and carried their child through to delivery are described.</p><p><strong>Methods: </strong>The first seven such women were enrolled and their clinical course is described.</p><p><strong>Main outcome measures: </strong>The primary outcome was a description of the experience and clinical effectiveness of CAB/RPV when used through pregnancy.</p><p><strong>Results: </strong>Initially, CAB/RPV was discontinued after pregnancy was confirmed and oral antiretroviral therapy was initiated instead. With evolving information on the safety and pharmacokinetics of cabotegravir and rilpivirine and advancing clinical experience, CAB/RPV given every 2 months was continued through pregnancy and oral antiretroviral therapy was added at 34-36 weeks gestation up until delivery to address the potential for subtherapeutic levels of cabotegravir and/or rilpivirine. In one individual where oral therapy was not an option, CAB/RPV was administered monthly from 20 weeks' gestation. All women maintained an undetectable viral load at the time of delivery.</p><p><strong>Conclusions: </strong>With the challenges and potential risks associated with interrupting CAB/RPV before or during pregnancy, we have established an approach to address this. Maintaining CAB/RPV q monthly or supplementing CAB/RPV q2 months with oral therapy starting at 34-36 weeks' gestation until delivery are potential approaches that allow CAB/RPV to be administered uninterrupted during pregnancy.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1832-1835"},"PeriodicalIF":2.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2026-12-01Epub Date: 2026-08-06DOI: 10.1097/QAD.0000000000004593
Samuel M Jenness, Bevin Manuelpillai, Steven M Goodreau, Julia L Marcus, Eva A Enns, Irah L Lucas, Cristian Acero Martinez, Aaron J Siegler, Travis Sanchez
{"title":"Evolving drivers of preexposure prophylaxis discontinuation among US MSM.","authors":"Samuel M Jenness, Bevin Manuelpillai, Steven M Goodreau, Julia L Marcus, Eva A Enns, Irah L Lucas, Cristian Acero Martinez, Aaron J Siegler, Travis Sanchez","doi":"10.1097/QAD.0000000000004593","DOIUrl":"10.1097/QAD.0000000000004593","url":null,"abstract":"<p><strong>Objective: </strong>To examine temporal trends in reasons for stopping preexposure prophylaxis (PrEP) among MSM from 2018 to 2024, including how reasons co-occur and vary by demographics.</p><p><strong>Design: </strong>Pooled repeated cross-sectional analysis of seven annual waves of the American Men's Internet Survey (AMIS), a national behavioral survey of US cisgender MSM ( N = 54 612).</p><p><strong>Methods: </strong>Among 3074 noncurrent PrEP users who reported reasons for stopping, we collapsed checklist items into six thematic categories and estimated adjusted prevalence by survey year using multivariable logistic regression with g-computation. Latent class analysis (LCA) identified subgroups with distinct discontinuation profiles.</p><p><strong>Results: </strong>The most common reason was Altered Sexual Activity (55%), followed by Side Effects (31.6%) and Financial/Access (29.4%). After demographic adjustment, Altered Sexual Activity rose from 46.2% in 2018 to 61.2% in 2024 [adjusted odds ratio (aOR) 1.93], and Privacy/Discrimination roughly doubled from 5.6 to 11.3%, the only reason with a significant linear trend (aOR 1.14 per year; P = 0.003). Financial/Access remained stable at approximately 29% across all 7 years. LCA identified three classes: Changed Circumstances (35.1%), Structural Barriers (23.8%), and Clinical/Multi-Barrier (41.1%). Being uninsured was the strongest predictor of financial discontinuation (aOR 4.31).</p><p><strong>Conclusions: </strong>Over 7 years of PrEP scale-up, circumstance-driven discontinuation grew increasingly dominant while stigma-related discontinuation doubled and cost barriers persisted. Three distinct discontinuation profiles argue for tailored approaches: re-engagement pathways for those whose circumstances change, financial navigation for structural barriers, and comprehensive clinical support for those experiencing multiple challenges.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1885-1894"},"PeriodicalIF":2.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13633502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2026-12-01Epub Date: 2026-10-29DOI: 10.1097/QAD.0000000000004600
Alan E Greenberg
{"title":"Global analysis of preexposure prophylaxis-to-need ratios in 2025.","authors":"Alan E Greenberg","doi":"10.1097/QAD.0000000000004600","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004600","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"40 12","pages":"1901-1902"},"PeriodicalIF":2.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149317112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2026-12-01Epub Date: 2026-07-27DOI: 10.1097/QAD.0000000000004589
Lizzie O'Brien, Samuel Cross, Namwa Wongkalasin, Andrew Hill
{"title":"Global analysis of pre-exposure prophylaxis to need ratios in 2025.","authors":"Lizzie O'Brien, Samuel Cross, Namwa Wongkalasin, Andrew Hill","doi":"10.1097/QAD.0000000000004589","DOIUrl":"10.1097/QAD.0000000000004589","url":null,"abstract":"<p><strong>Background: </strong>Despite substantial progress, global HIV incidence remains far above the UNAIDS 2030 target of 220 000 annual acquisitions. Pre-exposure prophylaxis (PrEP) is highly effective, including long-acting agents with 96-100% efficacy, but population-level impact depends on delivery at scale.</p><p><strong>Objective: </strong>To assess global PrEP coverage relative to need and estimate the implications for HIV epidemic control.</p><p><strong>Methods: </strong>We conducted a cross-sectional analysis of country-level HIV acquisitions and PrEP coverage across 184 countries using UNAIDS and supplementary data sources. For countries lacking 2025 data, the most recent estimates were used; PEPFAR-supported countries without current data were adjusted using a 34% reduction to reflect impact of funding cuts. We calculated the PrEP-to-need ratio (PrEP users per new HIV acquisition) and defined a target of 40 : 1, based on number-needed-to-treat estimates from recent trials.</p><p><strong>Results: </strong>Globally, 1.28 million new HIV acquisitions and 2.39 million PrEP users were identified, yielding a PnR of 1.88. Sixty-eight percentage of countries had low coverage (<1 : 1), including 78% of LMICs, which accounted for 89% of new acquisitions. Only four countries (2%) achieved the target PnR. Estimated PrEP coverage declined by 34% in PEPFAR-supported settings, with reductions up to 81% in some countries. Achieving target PnR globally would require approximately 51 million PrEP users.</p><p><strong>Conclusions: </strong>At present, PrEP is preventing only a fraction of the 1.3 million annual acquisitions, which are likely to rise over the coming years. Achieving global targets will require rapid expansion to tens of millions of users, alongside affordable pricing and renewed investment in prevention infrastructure.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1874-1884"},"PeriodicalIF":2.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148597688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}